OUR PIPELINE
We are building a gene therapy pipeline to help address the high unmet need for rare neurological diseases.
Focusing on the Future of Life-Changing Genetic Medicines
Gene therapy holds incredible promise to revolutionize medical treatment. At Neurogene we believe that innovation, robust scientific execution, and a strong sense of purpose are required to turn this promise into reality. Our focus is to develop life-changing genetic medicines for people and their families impacted by devastating neurological diseases.
Learn More >>
ABOUT US
At Neurogene, we are driven by a strong sense of purpose to advance genetic medicines.
LATEST NEWS
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates
On track to provide registrational trial plan update for NGN-401 gene therapy for Rett syndrome in the first half of…
Read MoreNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK --(BUSINESS WIRE)--May 8, 2025-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to…
Read MoreNeurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting
Presentation will highlight examples of successful surveillance and treatment of HLH in the context of gene therapy NEW YORK --(BUSINESS…
Read More